According to the study authors, D-allulose has a suppression response on glucose and insulin shown by the decrease in postprandial plasma glucose and insulin levels following the addition of D-allulose to sucrose in a dose-dependent manner
This approach mainly accounted for the possibility that a proportion of patients could have switched from DPP4 inhibitors to GLP1 receptor agonists during follow-up (a potential thyroid cancer risk with GLP1 receptor agonists could spill over into the group classified as receiving DPP4 inhibitors according to the intention-to-treat definition for drug use, which might lead to an underestimation of thyroid cancer risk with GLP1 receptor agonists)
Norris and others have now filed lawsuits against the manufacturers, including Novo Nordisk, the maker of Ozempic and Wegovy, and Lilly, the maker of Mounjaro
You May Lose Muscle Instead of Only Fat Protein and calories help protect lean mass
Patients in the treatment group had significantly lower LDL levels as compared with the placebo group, especially over the first 12 weeks of the trial